Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bleeding profile of prolonged-release dienogest + ethinyl estradiol vs flexible drospirenone + ethinyl estradiol regimen
2016-003831-39Phase 2Completed
- Sponsor
- Exeltis Santé
- Start
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Velmari, dienogest, drospirenone and ethinyl estradiol in contraception (4 arms), sponsored by Exeltis Santé. Primary endpoint: Total number of bleeding/spotting days. Started Feb 2017; status: completed.
02
Drugs
Velmaridienogestdrospirenoneethinyl estradiol
03
Conditions
contraception
Beyond the preview
Go deeper on 2016-003831-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003831-39.